Literature DB >> 27660574

Breaking Down the Barriers: Why the Delay in Referral for Pulmonary Arterial Hypertension?

Stacy A Mandras1, Hector O Ventura2, Paul A Corris3.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare and fatal disease. While many treatment options have been shown to improve quality of life, exercise tolerance, and hemodynamics in PAH, survival remains poor, in part due to the advanced stage at which patients present to PAH specialists.
METHODS: This perspective paper explores challenges related to the timing of referral, diagnosis, and initiation of therapy.
RESULTS: Multiple factors account for the delay in referral, including fallacies in physician education, commercial influence resulting in inappropriate prescribing practices, and barriers in access to care.
CONCLUSION: Improving physician education, encouraging the prescription of PAH medications to be done predominantly by PAH specialists, overcoming barriers to care, and promoting screening for PAH will help ensure early referral, diagnosis, and treatment.

Entities:  

Keywords:  Delayed diagnosis; early diagnosis; health services accessibility; hypertension–pulmonary; inappropriate prescribing; pulmonary medicine; referral and consultation

Year:  2016        PMID: 27660574      PMCID: PMC5024807     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  15 in total

1.  Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Lewis J Rubin
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

Review 2.  Pulmonary arterial hypertension.

Authors:  Vallerie V McLaughlin; Michael D McGoon
Journal:  Circulation       Date:  2006-09-26       Impact factor: 29.690

Review 3.  Updated treatment algorithm of pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Paul A Corris; Adaani Frost; Reda E Girgis; John Granton; Zhi Cheng Jing; Walter Klepetko; Michael D McGoon; Vallerie V McLaughlin; Ioana R Preston; Lewis J Rubin; Julio Sandoval; Werner Seeger; Anne Keogh
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

4.  Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns.

Authors:  Omar A Minai; Steven D Nathan; Nicholas S Hill; David B Badesch; James K Stoller
Journal:  Respir Med       Date:  2010-01-21       Impact factor: 3.415

5.  Targeting pulmonary vascular disease to improve global health: pulmonary vascular disease: the global perspective.

Authors:  Stuart Rich; Ahvie Herskowitz
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

Review 6.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 7.  Updated clinical classification of pulmonary hypertension.

Authors:  Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

8.  ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.

Authors:  Vallerie V McLaughlin; Stephen L Archer; David B Badesch; Robyn J Barst; Harrison W Farber; Jonathan R Lindner; Michael A Mathier; Michael D McGoon; Myung H Park; Robert S Rosenson; Lewis J Rubin; Victor F Tapson; John Varga
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

9.  Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study.

Authors:  Roderick C Deaño; Cherylanne Glassner-Kolmin; Melvyn Rubenfire; Adaani Frost; Scott Visovatti; Vallerie V McLaughlin; Mardi Gomberg-Maitland
Journal:  JAMA Intern Med       Date:  2013-05-27       Impact factor: 21.873

10.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Authors:  J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Oliver Distler; Dinesh Khanna; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; Martin Doelberg; Harbajan Chadha-Boreham; Harald Heinzl; Daniel M Rosenberg; Vallerie V McLaughlin; James R Seibold
Journal:  Ann Rheum Dis       Date:  2013-05-18       Impact factor: 19.103

View more
  1 in total

1.  Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center.

Authors:  Hongyang Pi; Chad M Kosanovich; Adam Handen; Michael Tao; Jacqueline Visina; Gabrielle Vanspeybroeck; Marc A Simon; Michael G Risbano; Aken Desai; Michael A Mathier; Belinda N Rivera-Lebron; Quyen Nguyen; Jennifer Kliner; Mehdi Nouraie; Stephen Y Chan
Journal:  Chest       Date:  2020-02-25       Impact factor: 9.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.